comparemela.com

Latest Breaking News On - Murali doraiswamy - Page 9 : comparemela.com

COMPASS Pathways: Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health

Two-Thirds Of Physicians Say Psilocybin Therapy Can Help Treatment-Resistant Depression, New Survey Shows

Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:CMPS) and Sermo announced on Wednesday findings from a survey of Sermo .

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.